Severe PTSD characterized by lower oxytocin and higher vasopressin levels

Research finds PTSD marked by reduced oxytocin and elevated vasopressin, suggesting AVP/OT ratios as potential biomarkers for diagnosis and treatment response.

K4Connect Raises $8.9M to Expand Tech Accessibility for Senior Living

What You Should Know: K4Connect, a Raleigh, NC-based mission-centered healthtech company and provider of enterprise operations tech for the senior living communities raises $8.9M in

July 25, 2023

Globus lays off Nuvasive employees after merger

Globus Medical is laying off staff after the company merged with spine specialist Nuvasive. In California alone, the company is cutting more than 150 positions,

January 26, 2024

Kymera’s protein degrader starts Phase II trial in atopic dermatitis

Share this article The Phase II trials for KT-474 in AD and HS are expected to be completed in Q1 2025. Image Credit: IrinaFoto /

December 8, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.